Kcnq2 Cure Alliance is ranked #7 of 11 disease & disorders organizations in Denver, CO, with an America's Best Score of 65 out of 100, based on its 2024 Form 990.
Kcnq2 Cure Alliance is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G20). Contributions are tax-deductible.
3700 Quebec St Unit 100 Pmb 118, Denver, CO 80207-1639
Among the 13 scored disease & disorders organizations in Denver, Kcnq2 Cure Alliance holds 170.3 months of operating reserves (peer median 11.4 months), runs a typical yearly surplus of 294.5% (peers: surplus of 3.1%), and has grown spending 40.5% a year (peers: grown spending 14.2% a year).
In fiscal year 2024 it reported $458,475 in revenue and $86,234 in expenses, with contributions making up 84.6% of revenue.
Kcnq2 Cure Alliance is a non-profit organization dedicated to raising research funds for kcnq2 epileptic encephalopathy, a rare and catastrophic form of epilepsy. By offering research grants for kcnq2 research with a novel approach, we can move researchers and the medical community forward to find better treatments and a cure while assisting afflicted individuals and their families.
Main program · fiscal year 2023
In collaboration with boston children's hospital the grant funded the acquisition and characterisation to an updated kcnq2 registry and draft natural history study of over 100 international patients. Countries thus involved and expanded in the study include bulgaria, china, australia, canada, norway, spain, croatia, united kingdom and the united states. Additionally, the grant research leads at bc… Read more
In collaboration with boston children's hospital the grant funded the acquisition and characterisation to an updated kcnq2 registry and draft natural history study of over 100 international patients. Countries thus involved and expanded in the study include bulgaria, china, australia, canada, norway, spain, croatia, united kingdom and the united states. Additionally, the grant research leads at bch are preparing a report on the overall statistical impact of building out a registry backed with published articles detailing the impact the data has provided to assist with the creation of human cell lines, crispr work and additional input to translational therapies such as rna and other gene therapy approaches.
$132,489 spent
Where each dollar went · fiscal year 2023
Of every dollar it spent, 99¢ went to programs, 1¢ to management and 0¢ to fundraising.
Programs $132,489
Management $1,892
Fundraising $10
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Operating reserves (reduced: more than 3 years of cash)
10+ yrs; 72.5 mo in cash
14.1 / 25
Financial balance (median margin)
+294.5%
1.9 / 20
Transparency
3 full 990s, latest TY2024
20 / 20
Program growth
+40.5% / yr
15 / 15
Track record
11 years
4.4 / 10
Debt load
0.9% of assets
10 / 10
Total
65.4 → 65
Spending on programs Not scored; America's Best needs 65%+
99%
Meets
Compared with Denver peers
Measure
This organization
Peer median
Operating reserves
10+ yrs
11.4 mo
Typical margin
+294.5%
+3.1%
Spending growth
+40.5% / yr
+14.2% / yr
Debt load
0.9%
8.1%
Peers: the 13 Denver disease & disorders organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$458,475Fiscal year 2024
Expenses$86,234Fiscal year 2024
Total assets$1,234,962Fiscal year 2024
Total liabilities$11,319Fiscal year 2024
Fiscal year ending December2024
Revenue$458,475
Expenses$86,234
Net income$372,241
Net assets$1,223,643
Notable sources of revenue
Percent of total revenue
Contributions
$387,797
84.6%
Program services
$0
0.0%
Investment income
$70,678
15.4%
Other (net)
$0
0.0%
Assets / debt
Total assets
$1,234,962
Total liabilities
$11,319
Net assets
$1,223,643
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$298,727
Expenses$134,391
Net income$164,336
Net assets$881,712
Notable sources of revenue
Percent of total revenue
Contributions
$290,960
97.4%
Program services
$7,767
2.6%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$881,712
Total liabilities
$0
Net assets
$881,712
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$172,403
Expenses$43,702
Net income$128,701
Net assets$730,127
Notable sources of revenue
Percent of total revenue
Contributions
$115,903
67.2%
Program services
$56,500
32.8%
Investment income
$0
0.0%
Other (net)
$0
0.0%
Assets / debt
Total assets
$730,127
Total liabilities
$0
Net assets
$730,127
Compensation
Officers and key employees
$0
Share of expenses
0.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?